Cysteine

Cysteine

SCHEMBL3396289

NC(CS)C(=O)O.OCC(O)CS

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.70
SLC7A11 Q9UPY5 1/20 0.70
LMNA P02545 1/20 0.56
SLC1A1 P43005 2/20 0.43
ENPEP Q07075 5/20 0.40
USP2 O75604 1/20 0.38
SLCO1B1 Q9Y6L6 1/20 0.38
OR51E2 Q9H255 1/20 0.37
GSR P00390 2/20 0.37
GRIK1 P39086 2/20 0.37
GRIK2 Q13002 2/20 0.37
GRM1 Q13255 2/20 0.37
GRM2 Q14416 2/20 0.37
SLC7A5 Q01650 1/20 0.37
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
CYP1A2 P05177 1/20 0.37
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cysteine SCHEMBL3396295 1.00 PTGS1 (0.70) PTGS1SLC7A11LMNASLC1A1ENPEP
Cysteine SCHEMBL888042 0.93 PTGS1 (0.73) PTGS1SLC7A11LMNASLC1A1ENPEP
Cysteine SCHEMBL888041 0.93 PTGS1 (0.73) PTGS1SLC7A11LMNASLC1A1ENPEP
Dl-Dithiothreitol SCHEMBL23883128 0.89 PTGS1 (0.55) PTGS1SLC7A11LMNASLC1A1ENPEP
Dl-Dithiothreitol SCHEMBL23883129 0.89 PTGS1 (0.55) PTGS1SLC7A11LMNASLC1A1ENPEP
Cystine SCHEMBL9615032 0.84 PTGS1 (0.48) PTGS1SLC7A11LMNASLC1A1ENPEP
Cystine SCHEMBL9615040 0.84 PTGS1 (0.48) PTGS1SLC7A11LMNASLC1A1ENPEP
Serine SCHEMBL17113864 0.84 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPGSR
Serine SCHEMBL1162414 0.84 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPGSR
Serine SCHEMBL1162408 0.84 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPGSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3902525-A1 OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OCULAR SURFACE DISEASE Surface Ophthalmics, Inc. (US) 2021-11-03 EP claimed
WO-2020139525-A1 OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OCULAR SURFACE DISEASE SURFACE PHARMACEUTICALS, INC. (US) 2020-07-02 WO claimed
WO-2014127015-A1 EPINEPHRINE FORMULATIONS FOR MEDICINAL PRODUCTS YS PHARM TECH (US) 2014-08-21 WO claimed
WO-2014127020-A1 EPINEPHRINE FORMULATIONS FOR MEDICINAL PRODUCTS YS PHARMTECH (US) 2014-08-21 WO claimed
WO-2014127018-A1 EPINEPHRINE FORMULATIONS FOR MEDICINAL PRODUCTS YS PHARMTECH (US) 2014-08-21 WO claimed
EP-0518905-B1 SILVER REMOVAL FROM PHOTOGRAPHIC PRODUCTS KODAK LTD (GB) 1994-06-29 EP claimed
EP-0518905-A1 SILVER REMOVAL FROM PHOTOGRAPHIC PRODUCTS. KODAK LTD (GB) 1992-12-23 EP claimed
WO-1991014205-A1 SILVER REMOVAL FROM PHOTOGRAPHIC PRODUCTS EASTMAN KODAK COMPANY (US) 1991-09-19 WO claimed
US-20230201632-A1 METHODS FOR FIXING HAIR AND SKIN GOLDMAN SACHS BANK USA 2023-06-29 US disclosed
US-20230104929-A1 METHODS FOR FIXING HAIR AND SKIN GOLDMAN SACHS BANK USA 2023-04-06 US disclosed
EP-4008306-A1 METHODS FOR FIXING HAIR AND SKIN Olaplex, Inc. (US) 2022-06-08 EP disclosed
US-11135150-B2 Compositions and methods for improving the quality of chemically treated hair L'OREAL (FR) 2021-10-05 US disclosed
CN-105431128-B Method for repairing hair and skin 奥拉普莱克斯股份有限公司 2021-07-30 CN disclosed
US-20210046334-A1 METHODS FOR FIXING HAIR AND SKIN GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT 2021-02-18 US disclosed
EP-1650191-A1 THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND METHOD OF TREATMENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH THE SAME DAINIPPON INK AND CHEMICALS, INC. (JP) 2006-04-26 EP disclosed
US-6706733-B2 THE BETA CRYSTAL FORM AND/OR GAMMA CRYSTAL FORM DAINIPPON INK AND CHEMICALS, INC. (JP) 2004-03-16 US disclosed
US-20030087929-A1 Quinolinone derivative formulation and its production method DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-05-08 US disclosed
CN-1396828-A Pharmaceutical composition comprising Pemetrexed together with monothioglycerol L-cystein or thioglycolic acid LILLY CO ELI (US) 2003-02-12 CN disclosed
EP-0298684-B1 CROSSLINKING REAGENTS USEFUL IN TREATING HAIR UNILEVER PLC (GB) 1993-04-21 EP disclosed
EP-0298684-A2 Crosslinking reagents useful in treating hair UNILEVER PLC (GB) 1989-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210046334-A1 METHODS FOR FIXING HAIR AND SKIN CUTA, SUCLG1, TST PTGS1 819/4885SLC7A11 860/4885LMNA 1250/4885
US-11135150-B2 Compositions and methods for improving the quality of chemically treated hair SRM, TET2, TET3 PTGS1 3609/4885SLC7A11 2196/4885LMNA 1181/4885
US-20230201632-A1 METHODS FOR FIXING HAIR AND SKIN CUTA, SUCLG1, TST PTGS1 819/4885SLC7A11 860/4885LMNA 1250/4885
US-20030087929-A1 Quinolinone derivative formulation and its production method CYP3A5, CYP2F1, CYP3A7 PTGS1 450/4885SLC7A11 389/4885LMNA 4186/4885
US-20230104929-A1 METHODS FOR FIXING HAIR AND SKIN CUTA, SUCLG1, TST PTGS1 819/4885SLC7A11 860/4885LMNA 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.